Company Update (NASDAQ:PPHM): Peregrine Pharmaceuticals Declares Quarterly Dividend On Its Series E Convertible Preferred Stock

Peregrine Pharmaceuticals (NASDAQ:PPHM) announced that its Board of Directors has declared a quarterly cash dividend payment on the Company’s 10.50% Series E Convertible Preferred Stock (the “Series E Preferred Stock”).

The quarterly dividend on the Series E Preferred Stock is payable on October 1, 2015 to holders of record at the close of business onSeptember 18, 2015.

The quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share, which is equivalent to an annualized 10.50% per share, based on the $25.00 per share stated liquidation preference, accruing from July 1, 2015 through September 30, 2015. The Series E Preferred Stock is listed on the NASDAQ Capital Market and trades under the ticker symbol “PPHMP”.  (Original Source)

Shares of Peregrine closed today at $1.25, up $0.07 or 5.93%. PPHM has a 1-year high of $1.75 and a 1-year low of $1. The stock’s 50-day moving average is $1.20 and its 200-day moving average is $1.33.

On the ratings front, Peregrine has been the subject of a number of recent research reports. In a report issued on July 16, Noble Financial analyst Rahul Jasuja initiated coverage with a Buy rating on PPHM and a price target of $5, which implies an upside of 303.2% from current levels. Separately, on the same day, Roth Capital’s Joseph Pantginis reiterated a Buy rating on the stock and has a price target of $5.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Rahul Jasuja and Joseph Pantginis have a total average return of -6.3% and -3.4% respectively. Jasuja has a success rate of 20.0% and is ranked #3055 out of 3747 analysts, while Pantginis has a success rate of 36.1% and is ranked #3594.

Peregrine Pharmaceuticals Inc is a biopharmaceutical company. It develops novel investigational products that help utilize the immune system to fight cancer, also known as immunotherapy.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts